Literature DB >> 20227932

Tissue microarray constructs to predict a response to chemoradiation in rectal cancer.

Sergio Huerta1, John Hrom, Xiaohuan Gao, Debabrata Saha, Thomas Anthony, Henry Reinhart, Payal Kapur.   

Abstract

PURPOSE: To identify, using tissue microarray (TMA), an immunohistochemical panel predictive of response to ionizing radiation (IR) in rectal cancer.
METHODS: TMA constructs were prepared from archived stage II/III rectal tumors and matching adjacent mucosa (n=38) from patients treated with pre-operative chemoradiation. Immunohistochemistry (IHC) was performed for MIB, Cyclin E, p21, p27, p53, survivin, Bcl-2, and BAX. Immunoreactivity along with clinical variables was subjected to univariate and forward stepwise logistic regression analyses.
RESULTS: Pathological complete response (pCR) was 23.9%. The number of positive lymph nodes obtained in the resected specimen was associated with pCR. Immunoreactivity for MIB (Sn 15%, Sp 65%, OR 0.33), p53 (Sn 3%, Sp 84%, OR 0.16), Bcl-2 (Sn 11%, Sp 74%, OR 0.35), and BAX (Sn 92%, Sp 80%, OR 46) was associated with pathological response (all p's<0.001). Forward stepwise logistic regression analysis demonstrated that MIB was an independent predictor of a response to chemoradiation (p=0.001).
CONCLUSIONS: A combined panel of mediators of apoptosis alone or combined with clinical factors is a feasible approach that can be applied to rectal tumor biopsies to predict a response to chemoradiation. The most sensitive factor was BAX; while MIB independently predicted a response to chemoradiation. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227932     DOI: 10.1016/j.dld.2010.02.003

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  13 in total

Review 1.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

2.  Interval between neoadjuvant chemoradiation and surgery for the management of rectal cancer.

Authors:  Sergio Huerta
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

3.  Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo; Takeshi Akiba; Shuichi Kawada
Journal:  Int J Clin Oncol       Date:  2015-04-02       Impact factor: 3.402

4.  BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  L Flanagan; A U Lindner; C de Chaumont; J Kehoe; J Fay; O Bacon; S Toomey; H J Huber; B T Hennessy; E W Kay; D A McNamara; J H M Prehn
Journal:  J Mol Med (Berl)       Date:  2014-11-13       Impact factor: 4.599

5.  On biomarkers and pathways in rectal cancer: What's the target?

Authors:  Gabriele Zoppoli; Valter Ferrando; Stefano Scabini
Journal:  World J Gastrointest Surg       Date:  2012-12-27

6.  Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection.

Authors:  Patricio M Polanco; Ali A Mokdad; Hong Zhu; Michael A Choti; Sergio Huerta
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

7.  Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival.

Authors:  Lana Bijelic; Anjali S Kumar; O Anthony Stuart; Paul H Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-26       Impact factor: 2.260

8.  High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.

Authors:  L Flanagan; J Kehoe; J Fay; O Bacon; A U Lindner; E W Kay; J Deasy; D A McNamara; J H M Prehn
Journal:  Radiat Oncol       Date:  2015-06-13       Impact factor: 3.481

9.  Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy.

Authors:  Abhishek A Solanki; Daniel T Chang; Stanley L Liauw
Journal:  Onco Targets Ther       Date:  2013-08-14       Impact factor: 4.147

10.  Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.

Authors:  Gaya Spolverato; Salvatore Pucciarelli; Roberta Bertorelle; Anita De Rossi; Donato Nitti
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.